Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FQGY7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,029
Award facts
- Contract value 100% obligated
- $5,028.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,028.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. The award, issued on January 21, 2026, is a firm fixed-price delivery order with an ultimate completion date of February 11, 2026, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The broader PPV-G GEN V program, valued at $30.3 billion, establishes multiple regional prime vendor contractors to supply pharmaceuticals and medical consumables to support Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the DLA's Medical Supply Chain division, with its product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's IDC under PPV-G GEN V, awarded on November 13, 2025, features a ceiling value of $499,999,999 with a 30-month base period and three 30-month option periods extending through December 31, 2036. This contract structure positions DMS Pharmaceutical Group as a critical pharmaceutical supplier serving the diverse medical supply requirements of military healthcare facilities globally, with the Nexplanon implant delivery order representing routine procurement under this comprehensive federal pharmaceutical supply framework.
Quick answers
Who was awarded contract SPE2DR26FQGY7?
SPE2DR26FQGY7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FQGY7 worth?
The government has obligated $5,029 on SPE2DR26FQGY7.
Is contract SPE2DR26FQGY7 an order under another contract?
Yes. SPE2DR26FQGY7 is a delivery order under SPE2DR25D9156, an indefinite delivery contract.
Was contract SPE2DR26FQGY7 competed?
The extent of competition for SPE2DR26FQGY7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award